Crypto Whales Are Loading Up — Are You?
New research shows the biggest crypto buyers are back. And this time? They could hold for the possibility that Bitcoin will surpass $100,000 in 2024. You don’t want to miss the next massive crypto bull run like we saw in 2020 and 2021. To know exactly what’s going on and what to buy… Get Access To Benzinga’s Best Crypto Research and Investments For Only $1.
Morgan Stanley provided its outlook on Akebia Therapeutics Inc (NASDAQ: AKBA) in a report published Tuesday. The company posted its Q2 results and announced the initiation of the Phase 3 clinical trials for vadadustat in dialysis.
Crypto Whales Are Loading Up — Are You?
New research shows the biggest crypto buyers are back. And this time? They could hold for the possibility that Bitcoin will surpass $100,000 in 2024. You don’t want to miss the next massive crypto bull run like we saw in 2020 and 2021. To know exactly what’s going on and what to buy… Get Access To Benzinga’s Best Crypto Research and Investments For Only $1.
ENTER TO WIN $500 IN STOCK OR CRYPTO
Enter your email and you'll also get Benzinga's ultimate morning update AND a free $30 gift card and more!
The Phase 3, which targets enrollment of 2,600 patients globally, will include a correction study of around 400 patients not currently being treated with Epo and a conversion study of around 2,200 currently receiving Epo who will be converted to either vadadustat or active control, with the goal of maintaining baseline hemoglobin levels.
The analyst currently have an Overweight rating with $17 price target, which is based on assumed 10 percent WACC and terminal value of 2.5x the 2030 cash flow.